Skip to main content

Syrrx Locks Onto $18.5M in Additional Private Equity

SAN FRANCISCO, Dec. 26 - Structural genomics company Syrrx said on Wednesday it received $18.5 million in its latest round of private equity funding.

 

The investment, led by Zurich, Switzerland-based HBM Partners, brings to $98.5 million Syrxx's total equity-investment pot, according to the company.

 

"Along with the $20 million debt financing arranged for our new facility earlier this year, this round of financing will assure investors that our operating funds will allow for the completion of our strategic plan through 2004," Norman Halleen, CFO of Syrrx, said in a statement.

 

Two weeks ago, Syrrx, based in San Diego, announced a research collaboration with Celera Genomics  under which Syrrx will receive a series of R&D payments to determine the three-dimensional structures of proteins identified by Celera as potential drug targets.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.